Trump claims China may give death penalty for fentanyl crimes involving US
Speaking as he signed anti-drug legislation on Wednesday, the US president said that the need to combat fentanyl was one of the reasons for his imposition of tariffs on countries across the world.
'I think we're going to work it out so that China is going to end up going from that to giving the death penalty to the people that create this fentanyl and send it into our country,' Trump said. 'I believe that's going to happen soon.'
China, which has long imposed severe penalties on people involved with drug distribution, including capital punishment, has been at the centre of Trump's ire over the opioid that helped fuel an overdose epidemic in the US.
The country raised outrage when it executed four Canadian dual citizens earlier this year for drug-related offences, despite pleas for clemency from the Canadian government.
Experts have questioned whether such penalties will help address the distribution of fentanyl, which China has said is driven largely by demand from people in the US.
Trump has previously linked his tariffs on countries such as Mexico and Canada to fentanyl, although trafficking from the latter into the US is close to nonexistent.
Drug overdoses in the US have been a subject of concern and political debate for years, with the country's opioid epidemic beginning with the aggressive promotion of painkillers by pharmaceutical companies but later being mostly driven by synthetic opioids such as fentanyl.
Overdose deaths have started to drop in recent years, giving experts cause for optimism after years of communities being ravaged by opioids. Overdoses over a 12-month period ending in June 2024 dropped by 12 percent compared with the same period the previous year, down from 113,000 to 97,000.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Jazeera
34 minutes ago
- Al Jazeera
White House says Trump is ‘open' to talks with Putin and Zelenskyy
The White House has said that United States President Donald Trump is 'open' to the idea of a meeting with Russian President Vladimir Putin and Ukrainian President Volodymyr Zelenskyy. In remarks on Wednesday, White House Press Secretary Karoline Leavitt said that Russian officials had expressed interest in meeting with Trump. Leavitt did not say when or where such a meeting could take place, but AP quoted an anonymous White House official saying the meeting could happen within a week. 'The Russians expressed their desire to meet with President Trump, and the president is open to meeting with both President Putin and President Zelenskyy,' Leavitt told members of the press following reports in the New York Times that Trump could meet with Putin in Russia as soon as next week. The US president has said that he is committed to helping bring the war in Ukraine to an end. He initially promised to stop the conflict on 'day one' of his presidency, but has struggled to make progress. The statement comes after US envoy Steve Witkoff visited Moscow to speak with Russian officials earlier today. In a social media post, Trump said Witkoff held a 'highly productive' meeting with Putin and that 'great progress was made!' 'Afterwards, I updated some of our European Allies. Everyone agrees this War must come to a close, and we will work towards that in the days and weeks to come,' he added. The New York Times reported that Trump intends to meet first with Putin before later setting up a meeting that would also include Zelenskyy. The news agency AFP reported that Trump also discussed the possibility of such a meeting during a phone call with Zelenskyy, citing an anonymous Ukrainian source. That call is also said to have included NATO Secretary General Mark Rutte and the leaders of Britain, Germany and Finland. Trump has recently mulled steps to further increase pressure on Russia, which he has accused of not being sincerely interested in ending the war. Such steps could include heightened US sanctions.
Al Jazeera
an hour ago
- Al Jazeera
Could Trump's trade strategy forge new alliances against him?
Russia, India, China and Brazil refuse to bend to US tariffs. Brazil, India, China and Russia remain firmly in Donald Trump's sights as targets for his tariffs. Others, like the European Union, have caved and negotiated deals. But could the United States president's confrontational stance forge new alliances, among those who have not, against Trump? Presenter: Adrian Finighan Guests: Einar Tangen – China specialist and senior fellow at the Taihe Institute Gustavo de Carvalho – Senior researcher in the geopolitics of the Global South at the South African Institute of International Affairs David McWilliams – Economist, author and podcast host
Al Jazeera
4 hours ago
- Al Jazeera
Wegovy maker Novo Nordisk warns of layoffs as competition grows
Novo Nordisk's outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be unavoidable as competition heats up against its blockbuster obesity drug Wegovy amid rising pressure from rival Eli Lilly. Novo Nordisk – which became Europe's most valuable company, worth $650bn, last year on booming sales of Wegovy – is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year, in part due to compounders who have been allowed to make copycat drugs based on the same ingredients as Wegovy due to shortages. Novo Nordisk, which according to its website has 77,000 employees, cut its full-year sales and profit forecasts last week, wiping $95bn off its market value since. The slide is a vast and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the company is eyeing potential cost-cutting measures. Layoffs loom 'We probably won't be able to avoid layoffs,' Jorgensen told Danish broadcaster DR. 'When you have to adjust a company, there are some areas where you have to have fewer people, some [areas] where you have to be smaller.' He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs – known as GLP-1 receptor agonists – was of 'equal size to our business' and compounded versions of Wegovy were sold at a 'much lower price point'. In May, Novo Nordisk said it expected many of the roughly one million US patients using compounded GLP-1 drugs to switch to branded treatments after a US Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million US patients were still using compounded GLP-1s and that the company's lowered outlook has 'not assumed a reduction in compounding' this year. 'The obesity market is volatile,' Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of the firm's new full-year guidance range would be for 'unforeseen events', such as stronger pricing pressure in the US than forecast, he said. The lower end of the range would imply sales around 150 billion Danish krone ($23bn) in the second half of 2025, compared with 157 billion krone ($24.5bn) in the same period last year. Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest US prescription data for Wegovy. While the drug was overtaken earlier this year by rival Eli Lilly's Zepbound in terms of US prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36 percent in the US and more than quadrupled in markets outside the US compared to a year ago, Novo Nordisk said. While Wegovy's US pricing held steady in the quarter, the company expected deeper erosion in the key US market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo Nordisk was expanding its US direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar 'cash sales' directly to patients, outside of insurance channels, in some markets outside the US. Cost cuts Novo Nordisk reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said the company was acting to 'ensure efficiencies in our cost base' as it announced it would terminate eight research and development projects. 'There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence,' Jefferies analysts said in a note. Investors have questioned whether the company can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendations on the stock since last week. Shares in Novo Nordisk plunged 30 percent last week – their worst weekly performance in over two decades. The stock has continued to tumble since the market opened in New York. As of 12pm local time (16:00 GMT), the pharmaceutical giant was down by more than 3.3 percent.
